Company / EPS (Diluted)
Idexx Laboratories EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$10.06
FY2025
5-year range
$4.89 / $10.06
FY2021-FY2025
Trend
+25.3%
vs FY2024
Sector context
#13 of 159
Health Care
What the data says
Among 159 Health Care companies, Idexx Laboratories is in the top 8% for eps (diluted). Improved from $8.60 to $10.06 over the past 2 years.
Based on SEC 10-K filings.
10.06 in FY2025 with a 5-year CAGR of +18.8%. Top quartile in the Health Care sector.
Improved from $8.60 to $10.06 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +14.5%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 159This company $10.06 Sector average $1.64
▼
+514.0% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 25.3% year-over-year.
- Ranks #13 out of 159 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.06 | +25.3% |
| FY2024 | $8.03 | -6.6% |
| FY2023 | $8.60 | +28.2% |
| FY2022 | $6.71 | +37.2% |
| FY2021 | $4.89 | +14.8% |
| FY2020 | $4.26 | +44.9% |
| FY2019 | $2.94 | +20.5% |
| FY2018 | $2.44 | +19.0% |
| FY2017 | $2.05 | +14.5% |
| FY2016 | $1.79 | +2.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026